Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C8H15N7O2S3
Número CAS:
Peso molecular:
337.45
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlegrade
pharmaceutical primary standard
API family
famotidine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1
InChI
1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
InChI key
XUFQPHANEAPEMJ-UHFFFAOYSA-N
Gene Information
human ... HRH2(3274)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Famotidine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
H2 histamine receptor antagonist; anti-ulcer agent
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
I C Wesdorp
Hepato-gastroenterology, 39 Suppl 1, 24-26 (1992-02-01)
Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GERD). From intraesophageal pH monitoring and clinical studies, b.i.d. dosing of this selective compound is necessary for achieving adequate results. The results of large
K Yoshimoto et al.
Clinical pharmacology and therapeutics, 55(6), 693-700 (1994-06-01)
Central nervous system toxicity of H2-receptor antagonists has rarely been confirmed by the respective elevated cerebrospinal fluid drug concentrations. We observed two hemodialyzed neurosurgical patients in whom mental deterioration and convulsions developed after intravenous famotidine therapy (10 and 40 mg/day).
H D Langtry et al.
Drugs, 38(4), 551-590 (1989-10-01)
Famotidine is a highly selective histamine H2-receptor antagonist. In healthy volunteers and patients with acid hypersecretory disease it is approximately 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and 8 times more potent than ranitidine